Marker Therapeutics (NASDAQ:MRKR) Stock Rating Raised to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Marker Therapeutics (NASDAQ:MRKR) from a hold rating to a strong-buy rating in a report released on Thursday,Zacks reports.

Several other brokerages have also recently issued reports on MRKR. Weiss Ratings cut shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Marker Therapeutics Trading Up 13.0%

NASDAQ:MRKR traded up $0.12 during mid-day trading on Thursday, reaching $1.04. The company’s stock had a trading volume of 1,145,148 shares, compared to its average volume of 86,015. The stock has a market cap of $17.34 million, a P/E ratio of -2.54 and a beta of 1.53. The firm’s fifty day moving average price is $1.17 and its two-hundred day moving average price is $1.33. Marker Therapeutics has a 12-month low of $0.84 and a 12-month high of $2.46.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.16. Analysts predict that Marker Therapeutics will post -0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Marker Therapeutics stock. Renaissance Technologies LLC grew its holdings in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 41.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 175,294 shares of the company’s stock after acquiring an additional 51,644 shares during the period. Renaissance Technologies LLC owned about 1.05% of Marker Therapeutics worth $228,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s approach uses tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of addressing the heterogeneity of solid tumors and potentially reducing the likelihood of treatment resistance.

Marker’s lead program is MT-601, an autologous multi-antigen-specific T-cell therapy being evaluated for pancreatic ductal adenocarcinoma.